SPDL1 and cancer: Solorzano-Ibarra et al. have demonstrated that identifying patients with high levels of sPD-L1 may aid in evaluating antibody therapy (Solorzano-Ibarra et al. 2021).PD-1/PD-L1 immune checkpoint blockade enhances the cellular immune response against cancer.